Endothelin at pathophysiological concentrations mediates coronary vasoconstriction via the endothelin-A receptor

C. R. Cannan, John C Jr. Burnett, R. R. Brandt, Amir Lerman

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Background: Endothelin-1 (ET-1) is an endothelium-derived vasoconstrictor peptide. Controversy persists regarding the predominant ET receptor that mediates coronary vasoconstriction at pathophysiological concentrations. The aim of the present study was to test the hypothesis that ET mediates local coronary vasoconstriction via the ET-A receptor at low concentrations of exogenous ET-1 designed to mimic pathophysiological states compared with pharmacological concentrations. Methods and Results: ET-1 (group 1, n=5) or sarafotoxin, a specific ET-B receptor agonist (group 3, n=6) (each at 2 ng/kg per minute), was infused into the left circumflex coronary artery in the anesthetized dog. In group 2 dogs (n=5), the same dose of ET-1 was infused with 4 μg/kg per minute of the specific ET-A receptor antagonist FR-139317. In group 4 (n=5), the same dose of sarafotoxin was infused with 50 μg/kg per minute of the specific inhibitor of nitric oxide formation, N(G)-monomethyl- L-arginine (L-NMMA). No difference in hemodynamics, coronary blood flow (CBF), coronary vascular resistance (CVR), or coronary artery diameter (CAD) was observed at baseline between the groups. In group 1, intracoronary ET-1 significantly decreased CBF and CAD in association with an increase in CVR. The percentage decrease in CBF and CAD in the group that received ET-1 and the ET-A receptor antagonist (group 2) was significantly less than that in the group that received ET-1 alone (group 1) (-12±3% versus -48±6% [P<.001] and -4.6±0.8 versus 1.0±0.3 [P<.05], respectively). The administration of the ET-A receptor antagonist (group 2) abolished the ET-mediated increase in CVR (7±5% versus 105±21%, P<.005). There was no significant effect on CBF, CVR, or CAD in the group receiving sarafotoxin alone (group 3). The administration of L-NMMA and sarafotoxin (group 4) resulted in a significant percentage decrease in CBF compared with the group that received sarafotoxin alone (-28±7% versus -8±2% [P<.05]). Conclusions: The present study demonstrates that low concentrations of exogenous ET-1, which may mimic pathophysiological concentrations, result in coronary vasoconstriction mediated predominantly via the ET-A receptor because such vasoconstriction is significantly attenuated by blockade with FR-139317. The ET-B receptor may have a dual vasoconstriction and vasodilatory effect.

Original languageEnglish (US)
Pages (from-to)3312-3317
Number of pages6
JournalCirculation
Volume92
Issue number11
StatePublished - 1995

Fingerprint

Endothelin A Receptors
Endothelins
Endothelin-1
Vasoconstriction
Coronary Vessels
Vascular Resistance
omega-N-Methylarginine
Dogs
Vasoconstrictor Agents
Endothelium
Arginine
Nitric Oxide
Hemodynamics
Pharmacology
Peptides

Keywords

  • coronary
  • endothelin
  • receptors

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Endothelin at pathophysiological concentrations mediates coronary vasoconstriction via the endothelin-A receptor. / Cannan, C. R.; Burnett, John C Jr.; Brandt, R. R.; Lerman, Amir.

In: Circulation, Vol. 92, No. 11, 1995, p. 3312-3317.

Research output: Contribution to journalArticle

@article{654bdc9f98c34fd9b125119b1d8241a2,
title = "Endothelin at pathophysiological concentrations mediates coronary vasoconstriction via the endothelin-A receptor",
abstract = "Background: Endothelin-1 (ET-1) is an endothelium-derived vasoconstrictor peptide. Controversy persists regarding the predominant ET receptor that mediates coronary vasoconstriction at pathophysiological concentrations. The aim of the present study was to test the hypothesis that ET mediates local coronary vasoconstriction via the ET-A receptor at low concentrations of exogenous ET-1 designed to mimic pathophysiological states compared with pharmacological concentrations. Methods and Results: ET-1 (group 1, n=5) or sarafotoxin, a specific ET-B receptor agonist (group 3, n=6) (each at 2 ng/kg per minute), was infused into the left circumflex coronary artery in the anesthetized dog. In group 2 dogs (n=5), the same dose of ET-1 was infused with 4 μg/kg per minute of the specific ET-A receptor antagonist FR-139317. In group 4 (n=5), the same dose of sarafotoxin was infused with 50 μg/kg per minute of the specific inhibitor of nitric oxide formation, N(G)-monomethyl- L-arginine (L-NMMA). No difference in hemodynamics, coronary blood flow (CBF), coronary vascular resistance (CVR), or coronary artery diameter (CAD) was observed at baseline between the groups. In group 1, intracoronary ET-1 significantly decreased CBF and CAD in association with an increase in CVR. The percentage decrease in CBF and CAD in the group that received ET-1 and the ET-A receptor antagonist (group 2) was significantly less than that in the group that received ET-1 alone (group 1) (-12±3{\%} versus -48±6{\%} [P<.001] and -4.6±0.8 versus 1.0±0.3 [P<.05], respectively). The administration of the ET-A receptor antagonist (group 2) abolished the ET-mediated increase in CVR (7±5{\%} versus 105±21{\%}, P<.005). There was no significant effect on CBF, CVR, or CAD in the group receiving sarafotoxin alone (group 3). The administration of L-NMMA and sarafotoxin (group 4) resulted in a significant percentage decrease in CBF compared with the group that received sarafotoxin alone (-28±7{\%} versus -8±2{\%} [P<.05]). Conclusions: The present study demonstrates that low concentrations of exogenous ET-1, which may mimic pathophysiological concentrations, result in coronary vasoconstriction mediated predominantly via the ET-A receptor because such vasoconstriction is significantly attenuated by blockade with FR-139317. The ET-B receptor may have a dual vasoconstriction and vasodilatory effect.",
keywords = "coronary, endothelin, receptors",
author = "Cannan, {C. R.} and Burnett, {John C Jr.} and Brandt, {R. R.} and Amir Lerman",
year = "1995",
language = "English (US)",
volume = "92",
pages = "3312--3317",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Endothelin at pathophysiological concentrations mediates coronary vasoconstriction via the endothelin-A receptor

AU - Cannan, C. R.

AU - Burnett, John C Jr.

AU - Brandt, R. R.

AU - Lerman, Amir

PY - 1995

Y1 - 1995

N2 - Background: Endothelin-1 (ET-1) is an endothelium-derived vasoconstrictor peptide. Controversy persists regarding the predominant ET receptor that mediates coronary vasoconstriction at pathophysiological concentrations. The aim of the present study was to test the hypothesis that ET mediates local coronary vasoconstriction via the ET-A receptor at low concentrations of exogenous ET-1 designed to mimic pathophysiological states compared with pharmacological concentrations. Methods and Results: ET-1 (group 1, n=5) or sarafotoxin, a specific ET-B receptor agonist (group 3, n=6) (each at 2 ng/kg per minute), was infused into the left circumflex coronary artery in the anesthetized dog. In group 2 dogs (n=5), the same dose of ET-1 was infused with 4 μg/kg per minute of the specific ET-A receptor antagonist FR-139317. In group 4 (n=5), the same dose of sarafotoxin was infused with 50 μg/kg per minute of the specific inhibitor of nitric oxide formation, N(G)-monomethyl- L-arginine (L-NMMA). No difference in hemodynamics, coronary blood flow (CBF), coronary vascular resistance (CVR), or coronary artery diameter (CAD) was observed at baseline between the groups. In group 1, intracoronary ET-1 significantly decreased CBF and CAD in association with an increase in CVR. The percentage decrease in CBF and CAD in the group that received ET-1 and the ET-A receptor antagonist (group 2) was significantly less than that in the group that received ET-1 alone (group 1) (-12±3% versus -48±6% [P<.001] and -4.6±0.8 versus 1.0±0.3 [P<.05], respectively). The administration of the ET-A receptor antagonist (group 2) abolished the ET-mediated increase in CVR (7±5% versus 105±21%, P<.005). There was no significant effect on CBF, CVR, or CAD in the group receiving sarafotoxin alone (group 3). The administration of L-NMMA and sarafotoxin (group 4) resulted in a significant percentage decrease in CBF compared with the group that received sarafotoxin alone (-28±7% versus -8±2% [P<.05]). Conclusions: The present study demonstrates that low concentrations of exogenous ET-1, which may mimic pathophysiological concentrations, result in coronary vasoconstriction mediated predominantly via the ET-A receptor because such vasoconstriction is significantly attenuated by blockade with FR-139317. The ET-B receptor may have a dual vasoconstriction and vasodilatory effect.

AB - Background: Endothelin-1 (ET-1) is an endothelium-derived vasoconstrictor peptide. Controversy persists regarding the predominant ET receptor that mediates coronary vasoconstriction at pathophysiological concentrations. The aim of the present study was to test the hypothesis that ET mediates local coronary vasoconstriction via the ET-A receptor at low concentrations of exogenous ET-1 designed to mimic pathophysiological states compared with pharmacological concentrations. Methods and Results: ET-1 (group 1, n=5) or sarafotoxin, a specific ET-B receptor agonist (group 3, n=6) (each at 2 ng/kg per minute), was infused into the left circumflex coronary artery in the anesthetized dog. In group 2 dogs (n=5), the same dose of ET-1 was infused with 4 μg/kg per minute of the specific ET-A receptor antagonist FR-139317. In group 4 (n=5), the same dose of sarafotoxin was infused with 50 μg/kg per minute of the specific inhibitor of nitric oxide formation, N(G)-monomethyl- L-arginine (L-NMMA). No difference in hemodynamics, coronary blood flow (CBF), coronary vascular resistance (CVR), or coronary artery diameter (CAD) was observed at baseline between the groups. In group 1, intracoronary ET-1 significantly decreased CBF and CAD in association with an increase in CVR. The percentage decrease in CBF and CAD in the group that received ET-1 and the ET-A receptor antagonist (group 2) was significantly less than that in the group that received ET-1 alone (group 1) (-12±3% versus -48±6% [P<.001] and -4.6±0.8 versus 1.0±0.3 [P<.05], respectively). The administration of the ET-A receptor antagonist (group 2) abolished the ET-mediated increase in CVR (7±5% versus 105±21%, P<.005). There was no significant effect on CBF, CVR, or CAD in the group receiving sarafotoxin alone (group 3). The administration of L-NMMA and sarafotoxin (group 4) resulted in a significant percentage decrease in CBF compared with the group that received sarafotoxin alone (-28±7% versus -8±2% [P<.05]). Conclusions: The present study demonstrates that low concentrations of exogenous ET-1, which may mimic pathophysiological concentrations, result in coronary vasoconstriction mediated predominantly via the ET-A receptor because such vasoconstriction is significantly attenuated by blockade with FR-139317. The ET-B receptor may have a dual vasoconstriction and vasodilatory effect.

KW - coronary

KW - endothelin

KW - receptors

UR - http://www.scopus.com/inward/record.url?scp=0028808582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028808582&partnerID=8YFLogxK

M3 - Article

C2 - 7586319

AN - SCOPUS:0028808582

VL - 92

SP - 3312

EP - 3317

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 11

ER -